跳至主要内容
临床试验/NCT07222605
NCT07222605Enrolling By Invitation不适用

Research Study Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases

eQ8Health Corporation d/b/a CareONE Concierge1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2025年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
1,000
试验地点
1
主要终点
Patient and caregiver reports on device design and use

研究概览

简要总结

Primary Objective:

The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization.

Secondary Objective:

The secondary objective is to note areas of potential improvement in the progression of the subject's neurological disease and identify the potential for the MemorEM to treat neurological diseases other than Alzheimer's disease. The investigators are also interested in Alzheimer's variants like those with ApoE4 alleles (none of the participants in the 8-person pilot were Apo-E4 positive), known mutations causing early onset Alzheimer's, and Posterior Cortical Atrophy.

详细描述

Study Duration:

The study will be open-ended with patients continuing use of the MemorEM as they wish or when NeuroEM Therapeutics recalls the device. It is expected but optional that patients will use the devices for approximately two years.

Study Design:

This study will focus on the "patient experience" of using the MemorEM device over an extended time period. Patients will remain under the care of their physicians and will provide brief descriptions of their device experiences and any suggestions for improvements. This study will not require any interventions other than using the MemorEM device, which was rated as Non-Significant Risk by the Western IRB for the previous pilot trial including two extensions that raised no safety concerns over the two and a half years of treatment.

Study Population:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
45 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient diagnosed with a neurological disease involving aggregated proteins such as Alzheimer's and its variants, Parkinson's, Frontotemporal dementia, Amyotrophic lateral sclerosis, Tauopathies, and other related neurological diseases.
  • •Presence of a caregiver(s) responsible for ensuring treatment compliance and potentially with authority to make medical decisions for the patient if the patient is not competent to make those decisions.
  • •A statement from each patient's physician that indicates the patient has the ability to understand and consent on their own AND they have the willingness to sign CareONE's patient consent.

排除标准

  • •Patient has Seizures, Epilepsy, uncontrolled Depression, uncontrolled Bipolar disorder, psychotic disorders, alcoholism or drug addiction
  • •Presence of metal implants in the head, except for metal dental implants
  • •Patient has hypertension that is unresponsive to anti-hypertensive medications
  • •Patient has implanted medication pumps unless cleared by physician
  • •Patient has significant heart disease, as determined by a physician

研究组 & 干预措施

Patient Experience Arm

Active Comparator

干预措施: MemorEM (Device)

结局指标

主要结局

Patient and caregiver reports on device design and use

时间窗: Surveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.

The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information will be gathered via a monthly survey. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization.

次要结局

  • Reports of efficacy in treating a patient's neurological condition(Surveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.)

研究者

发起方
eQ8Health Corporation d/b/a CareONE Concierge
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验